3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial - Iveson, T J; Kerr, R S; Saunders, M P (Lancet Oncol, 2018)
et al.